

When the Blood Ages the Body: Clonal Hematopoiesis

ABSURD HEALTH INSTITUTE — MEDICAL CONCEPT PAPERS · VOLUME SIX · PAPER 17

**Research series:* Aging Immune System as Repair Organ*

**Article URL upon publication:* <https://absurd.health/research/volume-six/when-the-blood-ages-the-body-clonal-hematopoiesis/>*

Abstract (original summary). Acquired somatic mutations can drive expansion of blood-cell clones during aging, sometimes altering inflammatory biology beyond the marrow. This paper examines clonal hematopoiesis as a mechanism connecting renewing cell systems to vascular disease, while distinguishing gene-specific risk, observational association and the absence of established clone-directed preventive interventions for most carriers.

Aging changes who makes the blood

Blood stem cells acquire somatic mutations over time. Some mutated clones expand sufficiently to become detectable without overt hematologic cancer, a phenomenon called clonal hematopoiesis of indeterminate potential when diagnostic criteria are met. Human observational studies associate certain clonal mutations with increased atherosclerotic cardiovascular risk, and experimental work implicates altered inflammatory signaling. This offers a striking mechanism by which an age-related change in one renewing tissue can influence disease elsewhere.

Not every mutation has the same meaning

A clone's effects may depend on the affected gene, variant allele fraction, other blood abnormalities and surrounding immune environment. TET2-associated biology differs from JAK2-related myeloproliferative signaling. Some detected clones are small and never cause clinical problems; a marker of clonal expansion is not an automatic treatment indication. It would be equally mistaken to assume all age-related vascular disease originates in the marrow. Conventional atherosclerotic exposures and genetics remain important.

The systems-medicine contribution

The marrow can be viewed as a source of circulating cells that carry a persistent inflammatory bias. Such cells might affect vascular walls, tissue repair and responses to later injury. That helps explain how aging can spread across organs without a single universal 'aging hormone.' It also reveals an ethical problem for preventive testing: detecting uncertain risk can create anxiety and overtreatment when no proven intervention is matched to the result.

What remains unresolved

Most studies do not establish whether directly modifying a detected clone improves clinical outcomes. Treating a mutation as causal in an experiment is different from having a safe clinical strategy for the person carrying it. Future work must examine clone-specific risks, inflammation pathways and whether conventional risk reduction remains the most effective option. The Institute's key idea is that renewal systems can themselves acquire persistent states that reshape the body's environment.

A clinical thought experiment

Two people may have normal blood counts, yet one carries an expanded hematopoietic clone associated with altered inflammatory behavior. A routine complete blood count need not reveal this biological history. The finding is important because the same blood-cell system supplies multiple organs with immune participants. Still,

discovering the clone does not explain every symptom, nor does it establish a reason to remove it.

What would discriminate among explanations

Studies must separate clone size, gene identity, smoking and other conventional cardiovascular risk factors. A therapy preventing atherosclerosis without changing the clone might show that downstream inflammatory pathways are more practical targets. A treatment reducing clone frequency but producing no patient benefit would not justify its risk merely because a biomarker normalized.

Aging blood is not a uniform fluid

Hematopoietic stem and progenitor cells continually renew circulating blood lineages. Over time, some clones acquire somatic mutations that confer a relative competitive advantage, allowing their descendants to contribute a larger fraction of blood cells. Clonal hematopoiesis of indeterminate potential, or CHIP, refers to a defined situation in which certain acquired mutations are detected without meeting criteria for a hematologic malignancy. The condition is associated with aging and with increased risks in several disease domains. It is not the same as leukemia, and it should not be described as an inevitably progressive cancer.

The conceptual novelty is that blood production itself may become a source of altered inflammatory signaling. A clone carrying a mutation affecting epigenetic regulation or cellular response may produce immune descendants with different behavior. In experimental models, some mutation-associated inflammatory pathways contribute to vascular injury. But the effect is gene- and context-dependent; CHIP should not be reduced to 'mutant blood causes inflammation' as a universal rule.

Two possible pathways to cardiovascular risk

One pathway is direct alteration of myeloid-cell inflammatory function, which may affect atherosclerotic plaques and responses to vascular injury. A second is common causation: age, smoking and prior treatment exposures can increase both vascular risk and clonal hematopoiesis, making an association appear partly causal even when shared determinants contribute. Human observational studies can support risk prediction and plausibility without proving which patient has a clone-driven vascular process.

Moreover, not every clone carries the same implications. Mutation identity, clone size, blood counts and other clinical features may change the risk profile. A measurement cannot be interpreted responsibly without considering that context. Detecting a variant in blood also does not establish that it explains an individual's stroke or cardiac disease.

Why the concept matters to regeneration

Blood cells help remove debris, coordinate inflammation and support transitions between injury and repair. If some clonal populations respond differently to danger signals, they may influence the local environment experienced by injured tissues. That is a plausible extension from immune-cell biology, but proving it in humans requires correlating specific clones with defined repair outcomes, not just showing associations with age-related disease.

A useful study might track recovery after a standardized event, such as surgery, and compare inflammatory trajectories and function among participants with specified CHIP mutations and carefully matched controls. Researchers would have to account for baseline disease and treatment. If differences persist across multiple independent settings, the possibility that hematopoietic aging modifies regenerative competence becomes more

compelling.

Treatment implications require restraint

It is premature to conclude that identifying CHIP mandates a specific anti-inflammatory drug or antithrombotic regimen. Risk management should follow established clinical evidence for the patient, while specialized CHIP-related counseling and monitoring depend on the finding's context. A biological hypothesis does not justify aspirin or another medication merely because observational risk associations exist. Suppressing inflammation indiscriminately might also impair infection control or wound healing.

The underlying insight is that blood is not just a carrier of oxygen and metabolites; it is a changing population of cells with evolutionary histories. That population may influence how organs age and recover, but the causal contribution of any one clone must be demonstrated rather than presumed.

What a clinician can and cannot infer from a clone

The finding of clonal hematopoiesis may be relevant to risk assessment, but a mutation should not become an explanation for every subsequent health event. A patient with CHIP who experiences myocardial infarction may also have ordinary lipid, blood-pressure, smoking and diabetic risks. Deciding what caused that individual's event is substantially harder than measuring a statistical association across cohorts. It would be especially inappropriate to alter antiplatelet or anticoagulant treatment solely on the basis of a theoretical CHIP–inflammation link.

The stronger experimental question is gene-specific: do cells carrying a defined mutation produce altered inflammatory responses that can be shown to change vascular or repair outcomes? A clone-size relationship may strengthen interpretation, yet clone size itself could correlate with age and other exposures. Experimental and clinical studies must separate those contributions.

This is where the repair-code concept adds a plausible dimension: immune descendants of a clone could encounter a healing wound and alter its inflammatory trajectory. Whether they do so in people remains a focused hypothesis, not a demonstrated general cause of delayed recovery.

Clone size can be both cause and consequence

A larger blood-cell clone may generate more descendants carrying the same alteration, making its biological impact potentially greater. But clonal expansion can also reflect selection pressures created by inflammation or prior treatment. Thus finding a relationship between clone size and illness does not eliminate confounding. Clone identity, functional behavior and background exposures must be studied together.

A particularly informative finding would be a mutation-specific effect on wound recovery that persists after adjustment for cardiovascular disease and age, supported by mechanistic studies in matched cells. A less informative finding would be that people with large clones are simply older and sicker on average. The former would open a new repair pathway; the latter would strengthen risk prediction while leaving causation unresolved.

A critical distinction is that blood-forming clones also interact with the treatment history of the patient. Cancer therapies and other exposures can select some clonal populations, and the associated risks need not mirror those of naturally occurring clones. An observational study that pools them may obscure real heterogeneity.

Researchers interested in repair should define mutation class, clone fraction, prior exposures and the organ outcome in advance. Only then could an apparent link between hematopoietic aging and slow tissue recovery be interpreted as more than the accumulation of age-correlated measurements. The path from clone to specific

immune-cell behavior to organ dysfunction is what requires demonstration.

Selected scientific readings

• Jaiswal S et al. (2017). Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. New England Journal of Medicine. <https://www.nejm.org/doi/full/10.1056/NEJMoa1701719>

• López-Otín C et al. (2023). Hallmarks of aging: An expanding universe. Cell. <https://doi.org/10.1016/j.cell.2022.11.001>

This is an evidence-informed conceptual essay, not a systematic review, clinical trial, validated diagnostic instrument, or treatment recommendation.

Editorial status: substantially revised conceptual article. Evidence-informed, not peer-reviewed, not a systematic review or clinical treatment guidance.